I think insurers are generally reluctant to intervene in on-label treatment of life-threatening diseases, particularly where there might be political push back. So I suspect they will look for their savings elsewhere first.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.